Rituximab: all 1,389 studies that test it

Page 2 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.

• A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingNCT06136351Phase 2
• A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingNCT06086197Phase 2
• RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT LymphomaNot yet recruitingNCT06064344Not applicable
• Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06045247Phase 2
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
• Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid ArthritisRecruitingNCT06003283Phase 4
• A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT05991388Phase 2/3
• The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
• A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
• Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 2
• Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
• Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRecruitingNCT05926427Phase 2
• Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
• Delayed Tolerance Through Mixed ChimerismRecruitingNCT05900401Phase 1/2
• Comparison of a Personalized Maintenance Therapy With the Standard Treatment in PemphigusRecruitingNCT05898308Phase 4
• Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCTRecruitingNCT05896007Phase 2
• Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)RecruitingNCT05868837Phase 3
• Immune Thrombocytopenia Management in AdultsRecruitingNCT05861297Phase 4
• Rituximab in the First Episode of Paediatric Nephrotic SyndromeNot yet recruitingNCT05850546Phase 3
• Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic SyndromeRecruitingNCT05843968Phase 2
• Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSRecruitingNCT05834855Phase 3
• Anti-CD20 Antibodies for Treatment of SLE-PAHRecruitingNCT05828147Phase 4
• Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
• Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderRecruitingNCT05786040Phase 2
• Epcoritamab and Rituximab for First-line Follicular LymphomaRecruitingNCT05783609Phase 2
• A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
• Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled TrialRecruitingNCT05734794Phase 3
• The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
• Selinexor in Combination With MTX+Ritu to Treat R/R CNSLRecruitingNCT05698147Phase 1/2
• Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingNCT05645718Phase 2
• Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaRecruitingNCT05635162Phase 2
• Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT05600660Phase 2
• Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized TrialRecruitingNCT05596786Phase 3
• Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingNCT05583071Phase 2
• Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT05575973Phase 2
• Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaRecruitingNCT05504603Phase 2
• The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
• Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
• Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
• Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus NephritisRecruitingNCT05207358Phase 4
• Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
• Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good RespondersRecruitingNCT05136976Phase 3
• Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaRecruitingNCT05099471Phase 2
• IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingNCT05073250Phase 2
• Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingNCT05052528Phase 1
• Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaRecruitingNCT04998669Phase 2
• Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftRecruitingNCT04989491Phase 4
• Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLNot yet recruitingNCT04913103Phase 2
• Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04758975Phase 2
• PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
• Different Immunosuppressive Treatment in iMNRecruitingNCT04745728Phase 3
• Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaRecruitingNCT04737889Phase 2
• A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaRecruitingNCT04669171Phase 1/2
• Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.RecruitingNCT04627753Phase 2
• Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
• Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingNCT04404088Phase 2
• Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic PurpuraRecruitingNCT04323748Phase 1
• Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System InvolvementEnrolling by invitationNCT04323566Phase 2
• CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)RecruitingNCT04318678Phase 1
• GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)RecruitingNCT04196413Phase 1
• Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaRecruitingNCT04061512Phase 2/3
• A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisRecruitingNCT03952637Phase 1/2
• Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal LymphomaRecruitingNCT03746223Phase 2
• R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaRecruitingNCT03697356Phase 2
• T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasRecruitingNCT03653338Phase 1/2
• Autologous Stem Cell Transplantation in Patients With Systemic SclerosisRecruitingNCT03630211Phase 2
• Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 2
• [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS LymphomaRecruitingNCT03569995Phase 2
• Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT03523975Phase 1/2
• Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic SyndromeRecruitingNCT03501459Phase 3
• Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureRecruitingNCT03500731Phase 1/2
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingNCT03418038Phase 2
• Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingNCT03414502Phase 3
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingNCT01419561Phase 2
• Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRecruitingNCT00977977Phase 2
• Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaRecruitingNCT00412594Phase 2
• Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT05498220Phase 2Results posted
• Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabCompletedNCT05267054Phase 1/2Results posted
• A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT05144009Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell LymphomaActive, not recruitingNCT04980222Phase 2Results posted
• SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular LymphomaTerminatedNCT04762160Phase 2Results posted
• Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04665765Phase 2Results posted
• A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT04660799Phase 2Results posted
• Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04659044Phase 2Results posted
• Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in MalawiCompletedNCT04585893Phase 2Results posted
• FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHLCompletedNCT04555811Phase 1Results posted
• Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)Active, not recruitingNCT04375228Phase 2Results posted
• Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderTerminatedNCT04337827Phase 2Results posted
• Ibrutinib and Rituxan for Chronic GVHDTerminatedNCT04235036Phase 2Results posted
• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaTerminatedNCT04074330Phase 1/2Results posted
• A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)CompletedNCT04062448Phase 2Results posted
• Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04047797Phase 2Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedNCT04002401Phase 2Results posted
• Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)CompletedNCT03983018Phase 2Results posted
• Split-Dose R-CHOP for Older Adults With DLBCLActive, not recruitingNCT03943901Phase 2Results posted
• Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaTerminatedNCT03919175Phase 2Results posted
• Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLActive, not recruitingNCT03863184Phase 2Results posted
• Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeCompletedNCT03834688Phase 2Results posted

← Rituximab overview